202 related articles for article (PubMed ID: 24469044)
21. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
Moch H
Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708
[TBL] [Abstract][Full Text] [Related]
22. The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM(EL).
Guo Y; Schoell MC; Freeman RS
Oncogene; 2009 Apr; 28(16):1864-74. PubMed ID: 19305426
[TBL] [Abstract][Full Text] [Related]
23. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity of
Stransky LA; Vigeant SM; Huang B; West D; Denize T; Walton E; Signoretti S; Kaelin WG
Proc Natl Acad Sci U S A; 2022 Apr; 119(14):e2120403119. PubMed ID: 35357972
[TBL] [Abstract][Full Text] [Related]
25. Knockout of programmed cell death 5 (PDCD5) gene attenuates neuron injury after middle cerebral artery occlusion in mice.
Lu J; Jiang Z; Chen Y; Zhou C; Chen C
Brain Res; 2016 Nov; 1650():152-161. PubMed ID: 27608954
[TBL] [Abstract][Full Text] [Related]
26. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
Sufan RI; Jewett MA; Ohh M
Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
[TBL] [Abstract][Full Text] [Related]
27. Specific von Hippel-Lindau protein expression of clear cell renal cell carcinoma with "immunogenic" features.
Magyarlaki T; Buzogány I; Nagy J
Pathol Oncol Res; 2001; 7(1):42-5. PubMed ID: 11349220
[TBL] [Abstract][Full Text] [Related]
28. pVHL-mediated regulation of the anti-angiogenic protein thrombospondin-1 decreases migration of Clear Cell Renal Carcinoma Cell Lines.
Sevilla-Montero J; Bienes-Martínez R; Labrousse-Arias D; Fuertes-Yebra E; Ordóñez Á; Calzada MJ
Sci Rep; 2020 Jan; 10(1):1175. PubMed ID: 31980715
[TBL] [Abstract][Full Text] [Related]
29. The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis.
Schoenfeld AR; Parris T; Eisenberger A; Davidowitz EJ; De Leon M; Talasazan F; Devarajan P; Burk RD
Oncogene; 2000 Nov; 19(51):5851-7. PubMed ID: 11127815
[TBL] [Abstract][Full Text] [Related]
30. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
[TBL] [Abstract][Full Text] [Related]
32. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.
Ivanova AV; Ivanov SV; Danilkovitch-Miagkova A; Lerman MI
J Biol Chem; 2001 May; 276(18):15306-15. PubMed ID: 11278694
[TBL] [Abstract][Full Text] [Related]
33. Mdm2-mediated neddylation of pVHL blocks the induction of antiangiogenic factors.
Wolf ER; Mabry AR; Damania B; Mayo LD
Oncogene; 2020 Jul; 39(29):5228-5239. PubMed ID: 32555333
[TBL] [Abstract][Full Text] [Related]
34. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
Vaziri SA; Grabowski DR; Hill J; Rybicki LR; Burk R; Bukowski RM; Ganapathi MK; Ganapathi R
Anticancer Res; 2009 Aug; 29(8):2961-9. PubMed ID: 19661301
[TBL] [Abstract][Full Text] [Related]
36. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein.
Corn PG; McDonald ER; Herman JG; El-Deiry WS
Nat Genet; 2003 Nov; 35(3):229-37. PubMed ID: 14556007
[TBL] [Abstract][Full Text] [Related]
37. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.
Gao W; Li W; Xiao T; Liu XS; Kaelin WG
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1027-1032. PubMed ID: 28082722
[TBL] [Abstract][Full Text] [Related]
38. Loss of VHL promotes progerin expression, leading to impaired p14/ARF function and suppression of p53 activity.
Jung YS; Lee SJ; Lee SH; Chung JY; Jung YJ; Hwang SH; Ha NC; Park BJ
Cell Cycle; 2013 Jul; 12(14):2277-90. PubMed ID: 24067370
[TBL] [Abstract][Full Text] [Related]
39. Role of VHL gene mutation in human cancer.
Kim WY; Kaelin WG
J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
[TBL] [Abstract][Full Text] [Related]
40. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
He Z; Liu S; Guo M; Mao J; Hughson MD
Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
